SEC Form 4 · accession 0001810417-26-000021
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Ryan Sullivan
Officer — Chief Financial Officer
Period of report
Sep 10, 2026
Accepted (ET)
Sep 11, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001534120
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 10, 2026 | M | 10,185 | $8.04 | A | 50,085 | D | |
| Common StockF2 | Sep 10, 2026 | S | 10,185 | $17.6197 | D | 39,900 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $8.04 | Sep 10, 2026 | M | 10,185 | D | — | Jan 28, 2035 | Common Stock | 10,185 | 105,815 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.
- F2The reported securities were sold in multiple transactions at prices ranging from $17.17 to $17.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F3The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.